Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
- 353 Downloads
KeywordsListeria Pemetrexed Listeria Monocytogenes Malignant Pleural Mesothelioma Good Performance Status
CRS-207 is live-attenuated, double-deleted Listeria monocytogenes (LADD) engineered to express the tumor-associated antigen mesothelin which is highly expressed in malignant pleural mesothelioma (MPM). CRS-207 stimulates potent innate and adaptive immunity and in combination with chemotherapy may act synergistically to alter the tumor environment to be more susceptible to immune-mediated killing. Preliminary data of 32 patients who received CRS-207 in combination with pemetrexed/cisplatin showed 60% partial responses and 94% disease control. Low-dose cyclophosphamide (Cy) in combination with LADD improved immune and anti-tumor responses and overall survival in preclinical studies.
Up to 60 subjects are planned to be enrolled in 2 mutually exclusive, sequential cohorts at 5 clinical trial sites. Patients must be chemotherapy-naïve, have unresectable MPM, good performance status (ECOG 0 or 1) and adequate organ function. Eligible patients in Cohort 1 receive 2 prime vaccinations with CRS-207 (1 × 109 CFU; 250 mL IV over 2 hours) 2 weeks apart, followed by up to 6 cycles of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) 3 weeks apart and 2 CRS-207 boost vaccinations 3 weeks apart. Subjects are followed every 8 weeks until disease progression. Clinically stable patients continue CRS-207 maintenance vaccinations every 8 weeks. Patients in Cohort 2 receive low-dose Cy (200 mg/m2) 1 day prior to each CRS-207 vaccination. Objectives of the study are safety, immunogenicity, objective tumor responses and tumor marker kinetics.
- 1.Hassan , Antonia , Alley , et al: Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM). J Clin Oncol. 2015, 33 (suppl): abstr 7565Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.